Prostate cancer is one of the most common cancers among men, affecting millions worldwide. While some cases can be managed through surgery or radiation, hormone therapy is a widely used treatment option, especially for advanced-stage prostate cancer. But how effective is it? Does it truly stop cancer from spreading? And what are the potential downsides?
Hormone therapy for prostate cancer is very different from testosterone replacement therapy. In prostate cancer, treatment usually means androgen deprivation therapy (ADT) or other therapies that lower androgen levels or block androgen signaling in order to slow cancer growth. Whether ADT is appropriate depends on cancer stage, recurrence risk, metastatic disease and the overall treatment plan established by the patient’s oncology and urology team.
National Cancer Institute: Hormone Therapy for Prostate Cancer
What is Hormone Therapy for Prostate Cancer?
Hormone therapy, also known as androgen deprivation therapy (ADT), is designed to reduce the levels of male hormones (androgens) like testosterone, which fuel prostate cancer growth. Since prostate cancer cells rely on androgens to survive, cutting off their supply can significantly slow down cancer progression.
Types of Hormone Therapy
- Androgen Deprivation Therapy (ADT): Lowers testosterone levels to deprive cancer cells of their energy source.
- Anti-Androgens: Block the effects of testosterone on cancer cells.
- LHRH Agonists and Antagonists: Stop the production of testosterone by the testes.
When is Hormone Therapy Recommended?
Hormone therapy is often recommended for:
- Patients with advanced or metastatic prostate cancer.
- Men who are not candidates for surgery or radiation.
- Cases where cancer has returned after initial treatment.
- Those undergoing radiation therapy, to enhance its effectiveness.
- Patients with aggressive, high-grade prostate cancer that requires immediate intervention.
How Successful is Hormone Treatment for Prostate Cancer?
The effectiveness of ADT depends on the disease setting and the other treatments being used. It can delay progression and improve outcomes in selected patients, but doctors cannot predict exactly how long an individual cancer will remain sensitive to hormonal treatment. PSA trends, imaging and the overall clinical picture are used to monitor response.
Effectiveness in Reducing Tumor Size
Studies show that hormone therapy can dramatically shrink prostate tumors, often delaying the need for more aggressive treatments like chemotherapy.
Success Rates in Different Stages
- Early-stage prostate cancer: Used in combination with radiation therapy, hormone therapy significantly improves outcomes.
- Advanced prostate cancer: Helps manage symptoms and slow disease progression.
- Metastatic prostate cancer: Can prolong life and improve quality of life but is not curative.
- Recurrent prostate cancer: Hormone therapy can help slow the return of cancer after initial treatment.
Scientific Evidence Supporting Hormone Therapy
A detailed review of clinical studies showed that 41.33% of neoadjuvant trials and 52.22% of adjuvant trials provided conclusive evidence of superiority for the proposed therapeutic strategies [1].
Additionally, nearly half (47.27%) of published research articles linked to these trials demonstrated that the investigated treatments were superior to standard therapy. However, about one-third of clinical studies translated their findings into practice did not report conclusive results for either neoadjuvant (32%) or adjuvant (37.78%) hormone therapy.
Despite the extensive scientific and economic efforts invested in prostate cancer hormone therapy research, clinical benefits in terms of treatment response and prognosis were observed in only one-third of treated patients.
Survival Rates and Life Expectancy with Hormone Therapy
In prostate cancer, “hormone therapy” usually refers to androgen deprivation therapy (ADT), which lowers androgen levels or blocks androgen signaling. Its effect on survival depends on the cancer stage, risk group, other treatments being used, and the specific clinical setting. It is not the same as hormone replacement therapy.
Impact on Survival Rates
For selected patients, especially certain higher-risk or locally advanced cases, adding ADT to radiation can improve cancer outcomes compared with radiation alone. The benefit varies by risk group and treatment duration, so decisions should be individualized by the treating oncology team.
Combination with Other Treatments
Doctors often combine hormone therapy with radiation or chemotherapy for better outcomes. In high-risk patients, this combination has been shown to improve 10-year survival rates.
What Do the Statistics Say?
- Survival benefit cannot be summarized as a fixed number of years; it varies substantially by disease stage, tumor biology, treatment combination, response, age, and overall health.
- In some intermediate- and high-risk settings, clinical trials support combining radiation with a defined course of ADT, but the magnitude of benefit is not the same for every patient.
- Newer androgen-receptor and androgen-synthesis–targeted therapies can improve outcomes in selected advanced prostate-cancer settings, but benefit depends on the specific drug, disease state, and combination regimen.
Does Hormone Therapy Stop Prostate Cancer from Spreading?
Hormone therapy effectively slows or halts the spread of prostate cancer by depriving cancer cells of the hormones they need. However, it’s not always a permanent solution.
How It Works Against Metastasis
By reducing testosterone levels, hormone therapy can prevent cancer cells from multiplying and spreading to bones or other organs.
When It May Not Work
In some cases, prostate cancer can adapt and become resistant to hormone therapy. This condition is known as castration-resistant prostate cancer (CRPC).
What Happens When Hormone Therapy Fails?
Doctors may recommend second-line hormone therapies, targeted therapies, or immunotherapy to help manage resistant cancer.
Can Prostate Cancer Return After Hormone Therapy?
Yes, prostate cancer can return after hormone therapy, particularly if the cancer cells develop resistance.
Understanding Hormone-Resistant Prostate Cancer
Over time, some cancer cells may adapt to low testosterone levels, continuing to grow despite hormone therapy. When this happens, additional treatments like chemotherapy or new-generation hormone blockers may be required.
Effects on Quality of Life
A study of 52 men with prostate cancer found that androgen deprivation therapy (ADT) led to declines in physical function, increased fatigue, and more sleep problems [2]. Sexual function and activity also dropped significantly.
Many patients reported feeling depressed, struggling with body image, and facing social and emotional challenges. These findings highlight the need for a well-rounded approach to care that supports both physical health and emotional well-being.
Conclusion
Androgen deprivation therapy is an established part of prostate-cancer treatment in several clinical settings, but its role depends on disease stage, recurrence risk, metastatic status and the rest of the oncology treatment plan. It is not testosterone replacement therapy, and decisions about ADT should be made with the patient’s urologist and oncology team.
This article is for general education. Prostate-cancer treatment should be directed by a urologist and/or medical or radiation oncologist familiar with the patient’s stage, pathology, imaging and treatment history.
Written and medically reviewed by David Nazarian, MD — Board Certified in Internal Medicine.
References:
- Ramos-Barriga O, Padilla-Fernández B-Y, Valverde-Martínez S, Perán-Teruel M, Márquez-Sánchez M-T, Flores-Fraile M-C, Flores-Fraile J, Martin-Hernández M, Grinard-de-León E, García-Cenador M-B, et al. Evaluation and Effectiveness of Clinical Trials with Hormone Therapy in the Treatment of Prostate Cancer. Applied Sciences. 2022; 12(10):5059. https://doi.org/10.3390/app12105059
- Cappuccio, F., Buonerba, C., Scafuri, L. et al. Study on the Impact of Hormone Therapy for Prostate Cancer on the Quality of Life and the Psycho-Relational Sphere of Patients: ProQoL. Oncol Ther 13, 233–249 (2025). https://doi.org/10.1007/s40487-024-00313-3
